Is TB-500 the same as thymosin beta-4?

TB-500 is the synthetic 17-amino-acid active fragment of thymosin beta-4. The full thymosin beta-4 protein is 43 amino acids. Research literature uses both names sometimes interchangeably, but TB-500 is the commercially available research peptide.

What does TB-500 actually do at the molecular level?

TB-500/Tβ4 binds and sequesters G-actin, preventing premature polymerisation. This regulates cell motility, drives angiogenesis via VEGF upregulation, and accelerates wound healing (Goldstein 2005).

Are there human TB-500 clinical trials?

Yes — Crockford 2010 (cardiac repair trial, post-MI) and Sosne 2010 (corneal wound healing) are the most-cited human studies. Both used IV thymosin beta-4 at clinical doses.

TB-500 / Thymosin Beta-4: Complete UAE Research Deep Dive 2026

Published 23 June 2026 · REVIVE Peptides Research Desk · 10 min read

TL;DR. TB-500 is the 17-amino-acid active fragment of thymosin beta-4 (Tβ4). It binds G-actin to regulate cell motility, drives VEGF-mediated angiogenesis, and accelerates wound healing across cardiac, corneal, dermal, and tendon models. Human RCT data exists in cardiac (Crockford 2010) and corneal (Sosne 2010) contexts; musculoskeletal use is animal-research-led.

What Is Thymosin Beta-4?

Thymosin beta-4 (Tβ4) is a 43-amino-acid intracellular protein, ubiquitous across mammalian tissues. It is the primary actin-sequestering molecule in human cells — by binding monomeric G-actin and preventing premature polymerisation, it controls when and where cells extend, divide, and migrate.

"TB-500" refers to a synthetic 17-amino-acid fragment containing the active actin-binding region of Tβ4. In research literature the names are used somewhat interchangeably, but commercially the term TB-500 refers to the fragment supplied for research use.

Mechanism of Action

Action	How it works	Reference
Actin sequestration	Binds G-actin 1:1, regulates polymerisation	Safer 1991
Angiogenesis	Upregulates VEGF, promotes endothelial migration	Grant 1999
Anti-inflammatory	Suppresses NF-κB pathway	Sosne 2007
Stem cell recruitment	Mobilises progenitor cells to injury sites	Smart 2007
Anti-apoptotic	Protects cells from ischemic death	Bock-Marquette 2004

Key Clinical Trials

Crockford 2010 — Cardiac Repair Post-MI

Crockford et al. 2010 reviewed thymosin beta-4 cardiac trials, including phase 1 work in post-myocardial-infarction patients. IV Tβ4 at 42, 140, or 420 mg single doses showed acceptable safety; phase 2 cardiac repair trials followed. Animal model work (Bock-Marquette 2004) had previously shown Tβ4 could activate epicardial progenitor cells to regenerate heart muscle.

Sosne 2010 — Corneal Wound Healing

Sosne et al. tested topical Tβ4 (0.1% solution) for corneal wound healing in human patients. Results showed accelerated re-epithelialisation vs vehicle. The corneal indication remains one of the most clinically advanced Tβ4 applications.

Goldstein 2005 — The Mechanism Foundation

Goldstein's 2005 review consolidated the wound-healing mechanism work in animals — diabetic skin wounds, corneal burns, cardiac ischemia — showing consistent acceleration of healing across tissue types.

REVIVE LAB UAE does not publish dosing, titration or administration schedules. The published trial literature cited on this page is the appropriate reference for study design.

REVIVE supplies TB-500 as 5 mg vials. See our reconstitution calculator for the math.

TB-500 vs BPC-157 — Different Tools

The two peptides are often stacked or compared. The differences:

Property	TB-500	BPC-157
Primary mechanism	Actin sequestration + angiogenesis	Cytoprotection + angiogenesis (VEGFR2)
Best evidence for	Cardiac repair, corneal healing	GI tract, tendon, muscle
Human RCTs published	Yes (cardiac, corneal)	None published
Half-life	Long (days)	Short (hours)
Frequency	Weekly or twice-weekly	Daily

See our dedicated comparison: BPC-157 vs TB-500.

Researching TB-500 in the UAE?
REVIVE supplies TB-500 10 mg vials with HPLC certificates and cold-chain delivery.
View TB-500 vials →

What's Still Missing

No published musculoskeletal RCTs. Despite widespread research use for tendon/ligament repair, peer-reviewed human trials in that indication don't exist.
Cancer concerns remain theoretical. Because Tβ4 upregulates VEGF and angiogenesis, theoretical concern exists about pro-tumour effects. Goldstein 2017 reviewed this and concluded current evidence does not support a cancer risk in healthy tissue, but the question stays open.
Optimal dose and frequency are not standardised. Research protocols vary widely.

Order TB-500 in the UAE

HPLC-verified vials · Same-day Dubai dispatch · Cash on delivery · 24h nationwide.

Buy TB-500 › TB-500 UAE Page

Research use only. TB-500 supplied by REVIVE is labelled and sold strictly for in-vitro and research purposes — not for human consumption. This page is informational and is not a recommendation. Any question that touches human health belongs with a qualified physician — nothing here replaces individual medical supervision.

References

Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421–429.
Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179–189.
Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 suppression of corneal NFκB: a potential anti-inflammatory pathway. Exp Eye Res. 2007;84(4):663–669.
Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466–472.
Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177–182.